Antiretroviral resistance in HIV-infected Saudi children failing first-line highly active antiretroviral therapy

Annals of Saudi Medicine

Volumn 32, Issue 6, 2012, Pages 565-569

  Hajjar, Sami Hussain Al ^a   Frayha, Husn ^a   Althawadi, Sahar ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LOPINAVIR; PROTEINASE; TRANSCRIPTASE; VIRUS RNA;

ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CHILD; CLINICAL ARTICLE; CROSS RESISTANCE; FAMILY COUNSELING; FEMALE; GENE MUTATION; GENETIC CODE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MALE; PRIORITY JOURNAL; PROMOTER REGION; RETROSPECTIVE STUDY; SAUDI ARABIA; SCHOOL CHILD; TERTIARY HEALTH CARE; TREATMENT RESPONSE; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; DNA MUTATIONAL ANALYSIS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MUTATION; PREVALENCE; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; SAUDI ARABIA; TREATMENT FAILURE; VIRAL LOAD;

EID: 84873911891     PISSN: 02564947     EISSN: 09754466     Source Type: Journal    
DOI: 10.5144/0256-4947.2012.565     Document Type: Article

References (28)

1. UNAIDS, Progress Report 2010. Towards Universal Access: Scaling UP Priority HIV/AIDS interventions in The Health sector. Available at http://www.unicef.org/about/annualreport/files/Communication-AR-2010.pdf. Accessed November, 2, 2011.
2. Ghen TK, Aldrovandi GM. Review of HIV antiretroviral drug resistance. Pediatr Infect Dis J. 2008; 27:749-752.
3. Richman DD, Morton SC, Wrin T, Hellmann N, Berry S, Shapiro MF, Bozzette SA. The prevalence of antiretroviral drug resistance in the United States. 2004;18:1393-1401.
4. Tamalet C, Fantini J, Tourres C. Yahi N. Resistance of HIV -1 to multiple antiretroviral drugs in France: a 6-year survey (1997-2002) based on an analysis of over 7, 000 gentoyptes. AIDS. 2000;17:2383-2388.
5. Johann-Liang R, Lee SE, Fernandez A, Cervia J, Noel GJ. Genotypic characterization of human immunodeficiency virus type 1 isolated from vertically infected children with antiretroviral therapy experience. Pediatr Infect Dis J. 2000;19:363-364.
6. Brindeiro PA, Brindeiro RM, Moetensen C, Hertogs K, De Vroey V, Rubini NP, Sion FS, De Sa CA, Machado DM, Succi RC, Tanuri A. Testing genotypic and phenotypic resistance in human immunodeficiency virus type 1 isolates of clade B and other clades from children failing antiretroviral therapy. J Clin Micriobiol. 2002;40:4512-4519.
7. Simonetti SR, Schatzmayr HG, Simonetti JP. Human immunodeficiency virus type 1: drug resistance in treated and untreated Brazilian children. Mem Inst Oswaldo Cruz. 2003;98:831-837.
8. Mullen J, Leech S, O'Shea S, Chystie IL, Du Mont G, Ball C, Sharland M, Cottam F, Zuckerman M, Rice P, Easterbrook P. Antiretroviral drug reistance among HIV -1 infected children failing treatment. J Med Virol; 2002;68:299-304.
9. Machado Es, Lamber JS, Watson DC, Afonso AO, da Cunha SM, Nogueira SA, Caride E. Oleveira RH, Sill AM, DeVico A, Tanuri A. Genotypic resistance and HIV -1 subtype in Brazilian children on dual and triple combination therapy. J Clin Virol. 2004;30:24-31.
10. Ruel TD, Kamya MR, Li P, Pasutti W, Charlebois ED, Liegler T, Dorsey G, Rosenthal PJ, Havlir DV, Wong JK, Achan J. Early virologic failure and the development of antiretroviral drug resistance mutations in HIV -infected Ugandan children. JAIDS 2011;56:44-50.
11. Hanna GJ, D'Aquila RT. Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy. Clin Infect Dis 2001; 32:774-82.
12. The working group of antiretroviral therapy and medical management of HIV -infected children: Guidelines for the use of antiretroviral agents in Pediatric HIV -infected children. Oct 2006; Feb 2008. Available at http://www/aidsinfo.nih.gov/contentfiles/Pediatricguidelines.pdf.
13. Delaugerre C, Warszawski J, Chaix ML, Veber F, Macassa E, Buseyne F, Rouzioux C, Blanche S. Prevalence and risk factors associated with antiretroviral resistance in HIV -1 infected children. J Med Virol 2007; 79:1261-69.
14. Aboulker JP, Babiker A, Chaix ML. Compagnucci A, Darbyshire J, Debre M, Faye, Giaquinto C, Gibb DM, Harper L, Saidi Y, Walker AS. Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcome. AIDS 2004; 18 237-245.
15. Davies MA, Boulle A, Fakir T, Nuttall J, Eley B., Adherence to antiretroviral therapy in young children in Cape Town, South Africa, measured by medication return and caregiver self-report: a prospective cohort study. BMC Pediatr. 2008;8:34.
16. Gibb DM, Goodall RL, Giacomet V, McGee L, Compagnucci A, Lyall H; Paediatric European Network for Treatment of AIDS Steering Committee. Adherence to prescribed antiretroviral therapy in human immunodeficiency virus-infected children in the PENTA 5 trial. Pediatr Infect Dis J. 2003; 22:56-62.
17. Van Dyke RB, Lee S, Johnson GM, Wiznia A, Mohan K, Stanley K, Morse EV, Krogstad PA, Nachman S; Pediatric AIDS Clinical Trials Group Adherence Subcommittee Pediatric AIDS Clinical Trials Group 377 Study Team. Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection. Pediatrics, 2002.109(4):e61. http://www.ncbi.nlm.nih.gov/pubmed/11927734.
18. Katko E, Johnson GM, Fowler SL, Turner RB. Assessment of adherence with medications in human immunodeficiency virus-infected children. Pediatr Infect Dis J, 2001. 20: 1174-6.
19. Tan D, Walmsley S. Lopinavir plus ritonavir: a novel protease inhibitor combination for HIV infection. Expert review of anti-infective therapy 2007; 5: 13-28.
20. Taylor BS, Hunt G, Abrams EJ, Coovadia A, Meyers T, Sherman G, Strehlau R, Morris L, Kuhn L. Rapid development and antiretroviral drug resistance mutations in HIV -infected children less than two years of age initiating protease inhibitorbased therapy in South Africa. AIDS Res Hum Retroviruses 2011, March 23 [Epublished of print] accessed Pub Med 20 Nov 2011.
21. Clavel F, Hance AJ. HIV resistance: N Engl J Med 2004; 350:1023-35.
22. Winters MA, Bosch RJ, Albrecht MA, Katzenstein DA; AIDS Clinical Trials Group 364 Study Team. Clinical impact of the M184V mutation on switching to didanosine or maintenance lamivudine treatment in nucleoside reverse -transcriptase inhibitors-experienced patients. JID 2003; 188:537-40.
23. Ilina T, Parniak MA. Inhibitors of HIV -1 reverse transcriptase. Advances in Pharmacology 2008; 56:121-167.
24. Pellegrin I, Izopet J, Reynes J, Denayrolles M, Montes B, Pellegrin JL, Massip P, Puel J, Fleury H, Segondy M. Emergence of zidovudine and multidrug- resistance mutations in the HIV -resistance mutations in the HIV -1 reverse transcriptase gene in therapy naïve patients receiving stavudine plus didanosine combination therapy. AIDS 1999; 13:1705-09.
25. Ilina T, Parniak MA. Inhibitors of HIV -1 reverse transcriptase. Advances in Pharmacology 2008; 56:121-167.
26. Izopet J, Bicart-See A, Pasquier C, Sandres K, Bonnet E, Marchou B, Puel J, Massip P. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine. J Med Virol 1999; 59:507-11.
27. Montaner JS, Mo T, Raboud JM, Rae S, Alexander CS, Zala C, Rouleau D, Harrigan PR. Human immunodeficiency virus-infected persons with mutations conferring resistance to zidovudine showed reduced virologic responses to hydroxyurea and stavudine-lamivudine. J infect Dis 2000; 181:729-32.
28. Bacheler L, Jeffrey S, Hanna G, D'Aquila R, Wallace L, Logue K, Cordova B, Hertogs K, Larder B, Buckery R, Baker D, Gallagher K, Scarnati H, Tritch R, Rizzo C. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patient failing non-nucleoside reverse transcriptase inhibitor therapy. J Virol 2001; 75: 4999-5008.